A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
131 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Gsk Investigational Site
Buenos Aires, Argentina
Maria AndersRecruiting - Gsk Investigational Site
Buenos Aires, Argentina
Juan BandiRecruiting - Gsk Investigational Site
Buenos Aires, Argentina
Fernando GruzRecruiting - Gsk Investigational Site
Buenos Aires, Argentina
Marcela Paola Alicia De Sousa CoelhoRecruiting - Gsk Investigational Site
Ciudad AutOnoma de Buenos Aire, Argentina
Nora CejasRecruiting - Gsk Investigational Site
Ciudad Autonoma de Buenos Aire, Argentina
Matias BoriRecruiting - Gsk Investigational Site
Rosario, Argentina
Juan FavaretoRecruiting - Gsk Investigational Site
San Miguel de Tucumán, Argentina
Ana PalazzoRecruiting
- Gsk Investigational Site
Adelaide, South Australia, Australia
Edmund TseRecruiting - Gsk Investigational Site
Melbourne, Victoria, Australia
William KempRecruiting - Gsk Investigational Site
Parkville Melbourne, Victoria, Australia
Ashok RajRecruiting - Gsk Investigational Site
Murdoch, Western Australia, Australia
Oyekoya AyonrindeRecruiting - Gsk Investigational Site
Perth, Western Australia, Australia
Tim MitchellRecruiting
- Gsk Investigational Site
Calgary, Alberta, Canada
Henry NguyenRecruiting - Gsk Investigational Site
New Westminster, British Columbia, Canada
Steven Cheuk-Fung PiRecruiting - Gsk Investigational Site
Vancouver, British Columbia, Canada
Alnoor RamjiRecruiting - Gsk Investigational Site
London, Ontario, Canada
Mohammad Qasim KhanRecruiting - Gsk Investigational Site
Toronto, Ontario, Canada
Gerald ChanRecruiting - Gsk Investigational Site
Toronto, Ontario, Canada
Jordan FeldRecruiting - Gsk Investigational Site
Montreal, Quebec, Canada
Julian HercunRecruiting - Gsk Investigational Site
Terrebonne, Quebec, Canada
Yves RobitailleRecruiting
- Gsk Investigational Site
Esbjerg, Denmark
Mette Munk LauridsenRecruiting - Gsk Investigational Site
Hvidovre, Denmark
Lise Lotte GluudRecruiting - Gsk Investigational Site
Odense C, Denmark
Camilla HansenRecruiting
- Gsk Investigational Site
Angers, France
Jerome BoursierRecruiting - Gsk Investigational Site
Bobigny, France
Nathalie Ganne-CarrieRecruiting - Gsk Investigational Site
Créteil, France
Jean-Philippe RichardetRecruiting - Gsk Investigational Site
Lille, France
Philippe MathurinRecruiting - Gsk Investigational Site
Montpellier, France
José URSIC BEDOYARecruiting - Gsk Investigational Site
Rouen, France
Ghassan RiachiRecruiting
- Gsk Investigational Site
Bochum, North Rhine-Westphalia, Germany
Isabell HanitzRecruiting - Gsk Investigational Site
Berlin, Germany
Keikawus ArastehRecruiting - Gsk Investigational Site
Berlin, Germany
Muenevver DemirRecruiting - Gsk Investigational Site
Kiel, Germany
Rainer GuentherRecruiting - Gsk Investigational Site
Leipzig, Germany
Ingolf SchiefkeRecruiting - Gsk Investigational Site
Mainz, Germany
Christian LabenzRecruiting
- Gsk Investigational Site
Athens, Greece
Vasileios SevastianosRecruiting - Gsk Investigational Site
Athens, Greece
Evangelos CholongitasRecruiting - Gsk Investigational Site
Athens, Greece
George PapatheodoridisRecruiting
- Gsk Investigational Site
Bergamo, Italy
Stefano FagiuoliRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 27 Sept 2024
- Primary completion
- 2 Aug 2027
- Completion
- 7 Mar 2028
- Last update posted
- 1 Apr 2026
- Registered enrollment
- 393
- Registry id
- NCT06613698
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.